Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Prestige Consumer Healthcare Inc. (PBH : NYSE)
 
 • Company Description   
Prestige Consumer Healthcare Inc. is a consumer healthcare products company. Its diverse portfolio of brands include Monistat(R) and Summer's Eve(R) women's health products, BC(R) and Goody's(R) pain relievers, Clear Eyes(R) and TheraTears(R) eye care products, DenTek(R) specialty oral care products, Dramamine(R) motion sickness treatments, Fleet(R) enemas and glycerin suppositories, Chloraseptic(R) and Luden's(R) sore throat treatments and drops, Compound W(R) wart treatments, Little Remedies(R) pediatric over-the-counter products, Boudreaux's Butt Paste(R) diaper rash ointments, Nix(R) lice treatment, Debrox(R) earwax remover, Gaviscon(R) antacid in Canada, and Hydralyte(R) rehydration products and the Fess(R) line of nasal and sinus care products in Australia. Prestige Consumer Healthcare Inc., formerly known as Prestige Brands Holdings Inc., is based in Tarrytown, New York.

Number of Employees: 600

 
 • Price / Volume Information   
Yesterday's Closing Price: $78.62 Daily Weekly Monthly
20 Day Moving Average: 351,636 shares
Shares Outstanding: 49.42 (millions)
Market Capitalization: $3,884.98 (millions)
Beta: 0.43
52 Week High: $90.04
52 Week Low: $64.94
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -9.26% -11.98%
12 Week -2.87% -15.80%
Year To Date 0.68% -4.88%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
660 WHITE PLAINS ROAD
-
TARRYTOWN,NY 10591
USA
ph: 914-524-6800
fax: 302-674-5266
irinquiries@prestigebrands.com http://www.prestigebrands.com
 
 • General Corporate Information   
Officers
Ronald M. Lombardi - President and Chief Executive Officer
Christine Sacco - Chief Financial Officer & Chief Operating Officer
John E. Byom - Director
Celeste A. Clark - Director
James C. D'Arecca - Director

Peer Information
Prestige Consumer Healthcare Inc. (BJCT)
Prestige Consumer Healthcare Inc. (CADMQ)
Prestige Consumer Healthcare Inc. (APNO)
Prestige Consumer Healthcare Inc. (UPDC)
Prestige Consumer Healthcare Inc. (IMTIQ)
Prestige Consumer Healthcare Inc. (CYGN)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED PRODUCTS
Sector: Medical
CUSIP: 74112D101
SIC: 2834
Fiscal Year
Fiscal Year End: March
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/14/25
Share - Related Items
Shares Outstanding: 49.42
Most Recent Split Date: (:1)
Beta: 0.43
Market Capitalization: $3,884.98 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $1.19 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $4.76 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: 0.00
Estmated Long-Term EPS Growth Rate: 7.00% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/14/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 16.52
Trailing 12 Months: 17.35
PEG Ratio: 2.36
Price Ratios
Price/Book: 2.12
Price/Cash Flow: 15.08
Price / Sales: 3.41
EPS Growth
vs. Year Ago Period: 29.41%
vs. Previous Quarter: 8.20%
Sales Growth
vs. Year Ago Period: 7.05%
vs. Previous Quarter: 2.14%
ROE
06/30/25 - -
03/31/25 - 12.87
12/31/24 - 12.36
ROA
06/30/25 - -
03/31/25 - 6.78
12/31/24 - 6.39
Current Ratio
06/30/25 - -
03/31/25 - 4.20
12/31/24 - 3.68
Quick Ratio
06/30/25 - -
03/31/25 - 2.82
12/31/24 - 2.20
Operating Margin
06/30/25 - -
03/31/25 - 19.89
12/31/24 - 18.95
Net Margin
06/30/25 - -
03/31/25 - 18.86
12/31/24 - 19.13
Pre-Tax Margin
06/30/25 - -
03/31/25 - 24.98
12/31/24 - 24.82
Book Value
06/30/25 - -
03/31/25 - 37.04
12/31/24 - 36.20
Inventory Turnover
06/30/25 - -
03/31/25 - 3.31
12/31/24 - 3.35
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.55
12/31/24 - 0.56
Debt-to-Capital
06/30/25 - -
03/31/25 - 35.57
12/31/24 - 35.77
 

Powered by Zacks Investment Research ©